Phenylephrine was chosen not because it was better medicine, but because there was less risk of misuse.
For decades, Australians have reached for cold tablets in moments of discomfort, trusting that the decongestant inside would ease their suffering. Yet the active ingredient in most of those tablets — oral phenylephrine — has been shown by accumulating science to offer no meaningful relief for nasal congestion, performing no better than a placebo when swallowed. Its presence on pharmacy shelves is less a story of medical progress than of regulatory compromise: phenylephrine replaced a drug that worked, not because it worked better, but because it was harder to misuse. The question now before regulators and consumers alike is how long a known inefficacy can remain a quiet fixture of everyday medicine.
- Millions of people are spending money on cold tablets believing the decongestant inside will clear their airways — a belief the science no longer supports.
- Oral phenylephrine was never chosen for its effectiveness; it filled a gap left when pseudoephedrine was restricted in 2006 to curb its use in illegal drug manufacturing.
- The chemistry is unambiguous: swallowed phenylephrine is largely destroyed in digestion before it can reach nasal passages, while the same drug delivered as a spray works as intended.
- In 2023, a US FDA advisory committee concluded oral phenylephrine is no better than placebo, and by November 2024 the FDA had proposed removing it from over-the-counter products entirely.
- Australia's TGA is watching the FDA's process but has no active review underway, leaving the products on shelves and consumers without clear guidance.
- Effective alternatives exist — nasal sprays, saline rinses, pseudoephedrine behind the pharmacy counter — but most people don't know they've been reaching for the wrong thing.
Most Australians who buy cold and flu tablets expect the decongestant inside to work. The day formulas pair a pain reliever with a decongestant; the night versions add an antihistamine. It sounds like a sensible system. The problem is that the decongestant — phenylephrine — does almost nothing when swallowed in tablet form. The evidence is now consistent: oral phenylephrine does not meaningfully relieve nasal congestion.
Phenylephrine works well as a nasal spray, delivering the drug directly to blood vessels in the nasal passages and reducing swelling. But taken orally, it passes through the digestive system and only a tiny fraction reaches the bloodstream — not nearly enough to affect the nose. The drug that works in one form fails almost entirely in another.
The reason phenylephrine ended up in tablets at all has little to do with medicine. In the early 2000s, the standard oral decongestant was pseudoephedrine — effective, but also a key ingredient in manufacturing amphetamines. As illicit drug production surged, pharmacies became targets for break-ins and robberies. By 2006, pseudoephedrine was moved behind the counter, requiring pharmacist involvement. Pharmaceutical companies needed a replacement, and phenylephrine — already available as a nasal spray — was selected. Not because it was better, but because it posed less risk of diversion. Convenience for regulators and manufacturers, not benefit for patients.
The science has since caught up. Better-designed studies confirmed what earlier data hinted at: oral phenylephrine performs no better than placebo. In 2023, an FDA advisory committee reached that conclusion formally, and in November 2024 the FDA proposed removing oral phenylephrine from over-the-counter cold products altogether.
Australia's TGA is aware of the FDA's reasoning — which centres on efficacy, not safety — but has no current plans to conduct its own review. The products remain on shelves. Any relief people feel from these tablets almost certainly comes from the paracetamol or ibuprofen, not the decongestant.
For genuine nasal relief, options do exist: phenylephrine or oxymetazoline nasal sprays work, though only for up to three days before risking rebound congestion. Saline sprays are safe and effective without that risk. Pseudoephedrine still works and is still available in Australia, though it requires ID and a pharmacist's assistance. Beyond that, rest, fluids, and time remain the most honest remedies. A cold is a virus — no tablet cures it. But consumers at least deserve to know when a tablet isn't treating it either.
You wake up with a blocked nose and reach for the cold tablet on your bedside table. The packet promises fast relief—clearer sinuses, easier breathing, a way through the next few days. But the tablet you're swallowing almost certainly won't do what it claims.
Most Australians who buy over-the-counter cold and flu remedies expect them to work. The day versions typically contain paracetamol or ibuprofen for aches, paired with a decongestant. The night versions add an antihistamine to help you sleep. It sounds straightforward. The problem is the decongestant itself. In Australia, the most common one is phenylephrine—and when taken as a tablet, it doesn't meaningfully relieve nasal congestion. The evidence on this is now consistent and clear. Yet these products remain on pharmacy shelves across the country, sold to people who believe they're buying something that will actually help.
Phenylephrine works perfectly well as a nasal spray. Spray it directly into your nose and it narrows blood vessels in the nasal passages, reducing swelling and opening your airways. But swallow it in a tablet and almost nothing happens. The reason is simple chemistry: when phenylephrine is taken orally, only a tiny fraction of it enters the bloodstream. Not enough reaches the nose to have any real effect. A nasal spray delivers the drug directly to where it needs to go. A tablet sends it through your digestive system, where most of it is lost.
How did we end up here? The answer lies in Australia's drug problem of the early 2000s. Back then, the standard decongestant in cold tablets was pseudoephedrine. It worked well. But pseudoephedrine was also a key ingredient in manufacturing amphetamines—ice and speed. Between 1996 and 2005, as illicit drug production spiked, pharmacies became targets. Break-ins, ram raids, armed hold-ups. The risk was real and escalating. In 2006, the government tightened restrictions. Pseudoephedrine was reclassified as "pharmacist only"—still available without a prescription, but behind the counter, requiring a pharmacist's involvement. It became much harder to obtain, whether your intentions were legitimate or not.
Pharmaceutical companies needed a replacement. Phenylephrine, which had been available as a nasal spray since the 1990s, seemed like an option. Early studies suggested it might work as an oral decongestant. It wasn't chosen because it was better medicine. It was chosen because there was less risk of it being diverted for drug manufacturing. Phenylephrine replaced pseudoephedrine not on merit but on convenience—for regulators and manufacturers, if not for consumers.
But the science has moved on. In recent years, better-designed studies have painted a different picture. Oral phenylephrine performs no better than placebo. In 2023, an independent advisory committee to the US Food and Drug Administration reviewed the accumulated evidence and reached the same conclusion: at standard doses, it doesn't work. In November 2024, the FDA proposed removing oral phenylephrine from over-the-counter cold and flu products altogether.
Australia's Therapeutic Goods Administration is watching. A spokesperson confirmed the TGA is aware of the FDA's proposal and its reasoning—efficacy concerns, not safety concerns. But the TGA has no current plans to review oral phenylephrine itself. It will wait to see what the FDA decides. Meanwhile, the products stay on shelves. Australians keep buying them, paying for relief that doesn't come.
The safety question is straightforward: oral phenylephrine doesn't harm you. The real issue is that you're paying for a medicine that provides little to no benefit for the symptom you're trying to treat. If you feel better after taking a cold tablet, it's almost certainly because of the paracetamol or ibuprofen in it—the pain reliever, not the decongestant. For actual nasal congestion relief, a nasal spray containing phenylephrine, oxymetazoline, or xylometazoline works, but only for up to three days. Longer use causes rebound congestion—your symptoms worsen when you stop. Saline sprays or rinses offer safe, effective relief without that risk. Some people might benefit from pseudoephedrine, which still works and is still available in Australia, though you'll need to show ID and ask the pharmacist. Rest, fluids, steam, and time remain your best tools. A cold is a virus. No tablet cures it. But at least you can choose not to pay for one that doesn't even relieve the symptoms.
Citações Notáveis
The TGA is aware of the FDA's proposal based on efficacy concerns, not safety concerns, and will continue to monitor outcomes.— TGA spokesperson
A Conversa do Hearth Outra perspectiva sobre a história
So phenylephrine works fine as a spray but fails as a tablet. Why the difference?
It's about delivery. A spray puts the drug directly where it needs to act—on the blood vessels in your nasal passages. A tablet has to survive your stomach acid, get absorbed into your bloodstream, and then circulate to your nose. Most of it gets lost along the way. Only a tiny fraction ever makes it.
And this wasn't always known?
Early studies suggested it might work orally. But as research methods improved, the picture changed. Newer, better-designed trials showed it was no better than placebo. The evidence just kept pointing the same direction.
Why didn't the government switch back to pseudoephedrine once the drug manufacturing crisis cooled down?
That's the frustrating part. Pseudoephedrine was restricted because of a real problem—pharmacies were being targeted for break-ins. Once that restriction was in place, switching back would have meant undoing a policy that was seen as working. Phenylephrine was already in the market. Inertia took over.
So consumers are paying for a placebo essentially.
Not quite a placebo—the other ingredients like ibuprofen do help with aches and fever. But for the nasal congestion specifically, yes, you're paying for something that doesn't work. And you might not realize it because you feel better overall.
What's stopping Australia from following the FDA's lead?
The TGA is waiting to see what the FDA actually does. There's no urgency. The products aren't unsafe, just ineffective. And there's no political pressure yet. But once the FDA makes its final decision, Australia will likely face more scrutiny.
If someone has a blocked nose right now, what should they actually do?
A nasal spray with phenylephrine or saline will help. Or just wait—most colds clear in seven to ten days anyway. The hard truth is there's no cure, only symptom management. Rest and fluids matter more than any tablet.